Male gonadal dysfunction in Hodgkin's disease. A prospective study

Area of Science:

• Oncology
• Reproductive Endocrinology
• Male Infertility

Background:

• Hodgkin's disease is a cancer affecting the lymphatic system.
• Chemotherapy is a standard treatment for Hodgkin's disease.
• The impact of Hodgkin's disease and its treatment on male gonadal function requires thorough investigation.

Purpose of the Study:

• To prospectively assess the effects of Hodgkin's disease and chemotherapy on male gonadal function.
• To evaluate pre-treatment and post-treatment fertility parameters.
• To examine hormonal changes and their correlation with gonadal dysfunction.

Main Methods:

• Prospective study of 47 men with Hodgkin's disease.
• Assessment of gonadal function including sperm counts, hormone levels, and libido.
• Pre- and post-treatment testicular biopsy analysis.
• Evaluation of psychological effects during chemotherapy.

Main Results:

• Pre-treatment subfertility was observed in 43% of men, with impotence and low sperm counts.
• Eight of nine pretreatment testicular biopsies showed abnormalities.
• After two chemotherapy cycles, 14 of 14 men became azoospermic with elevated follicle-stimulating hormone.
• Post-treatment biopsies confirmed germ cell aplasia.
• Significant reduction in libido and increased irritability were reported during therapy.

Conclusions:

• Cytotoxic chemotherapy is a primary cause of irreversible infertility in men treated for Hodgkin's disease.
• A notable proportion of men exhibit pre-existing gonadal dysfunction prior to initiating treatment.
• The study highlights the critical need for fertility preservation strategies in young men undergoing chemotherapy.